Articles related to RESPIRATORY HEALTH

A double-blind, placebo-controlled randomized clinical trial including people with COPD and chronic breathlessness was conducted at 20 Australian medical centers. One-hundred sixty participants were randomized to oral extended-release morphine versus placebo. The change in the intensity of worst breathlessness at week 1 was not significantly different between the morphine group and the placebo group.

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

A comprehensive review on the widespread uptake of vaping, including its origins and history, a timeline of discoveries, terminology, epidemiology, its use as a “harm reducer,” clinical presentations of vaping lung injuries (including an overview of the 2019 EVALI outbreak), the pathophysiology of vaping-induced lung injury, clinical aspects including outcomes, COVID-19 considerations, future directions, guidelines, and questions for future research.